Moderna Inc
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →
Analyst Sentiment
Moderna faces potential headwinds at current valuations. Our analysis suggests 16.1% downside risk to our $115.71 target. Investors may want to consider reducing exposure or waiting for a better entry point.
The 24/7 Factor
5-Year Projection
Prediction History
| Date | Price Target | Stock Price | Rating | Upside |
|---|---|---|---|---|
| $115.71 | $137.99 | SELL | −16.1% | |
| $99.07 | $145.13 | SELL | −31.7% | |
| $55.26 | $63.32 | HOLD | −12.7% | |
| $55.26 | $59.17 | HOLD | −6.6% | |
| $54.01 | $54.82 | HOLD | −1.5% | |
| $54.06 | $57.02 | HOLD | −5.2% | |
| $52.84 | $68.28 | SELL | −22.6% |
Social Sentiment
Frequently Asked Questions
What is the MRNA stock price prediction for 2030?
Looking ahead to 2030, our model projects MRNA could trade at an average price of $112.44, with a potential range between $84.33 and $140.55. This represents a potential 18.5% decline from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.
Is MRNA a buy, sell, or hold right now?
24/7 Wall St. currently rates MRNA as a SELL. Significant downside (-16.1%) Among Wall Street analysts, 4 rate it Buy, 16 rate it Hold, and 3 rate it Sell.
What is the MRNA stock price target in an optimistic scenario?
Our optimistic scenario for MRNA projects a price of $139.29 over the next 12 months. This represents modest upside of 0.9% from today’s price, suggesting the stock may be fairly valued at current levels even under favorable conditions.
What is the downside risk for MRNA stock?
In our conservative scenario, MRNA could trade as low as $84.10 over the next 12 months, representing a 39.1% decline from current levels. This scenario accounts for potential headwinds including earnings misses, competitive pressures, or broader market weakness.
Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →